Combination of mass based systems with expanded synthesis capacity creates a state-of-the-art manufacturing environment for achieving the highest throughput and quality
Sigma-Genosys, a division of Sigma-Aldrich, has expanded its portfolio of technologies to support its rapidly growing custom peptide business.
Central to this expansion is the introduction of mass-based purification systems.
LC/MS purification has supplanted conventional, less-specific UV detectors, as the method of choice for peptide purification.
The utilization of this technology in the Sigma-Genosys manufacturing process has significantly increased throughput.
In addition, analytical capabilities have been augmented by the introduction of MS/MS detection.
This combination of mass based systems with expanded synthesis capacity creates a state-of-the-art manufacturing environment for achieving the highest throughput and quality.
"This significant financial investment reinforces our commitment to the custom peptide market, ensuring integrity and accuracy of quality peptide production and rapid delivery to our growing customer base," said Shaf Yousaf, president of Sigma-Aldrich's research biotech business unit.
"It is our goal to become the premier quality supplier of custom manufactured peptide services to leading pharmaceutical and biotechnology companies worldwide".
Sigma-Genosys continues to evaluate and implement cutting-edge technologies for continued improvements in product quality and services.
These recent investments, in conjunction with ISO:9001 certified manufacturing processes, ensure customers are provided with the highest quality peptides.
